Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

January 25, 2020

Study Completion Date

January 9, 2021

Conditions
Treatment Resistant Depression
Interventions
DEVICE

Active TBS-DLPFC

"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."

DEVICE

Sham TBS-DLPFC

The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

DEVICE

Open label TBS-DLPFC

"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."

Trial Locations (1)

94305

Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT03068715 - Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD) | Biotech Hunter | Biotech Hunter